Trial reportBioMed research international2026
Effects of Ubiquinol on Oxidized Low-Density Lipoprotein in Prediabetic Patients: A Randomized, Double-Blinded, Placebo-Controlled Study.
Trial report in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of Ubiquinol on Oxidized Low-Density Lipoprotein in Prediabetic Patients: A Randomized, Double-Blinded, Placebo-Controlled Study.BioMed research international · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objectives: Oxidized low-density lipoprotein (oxLDL) has emerged as a promising biomarker of oxidative burden and cardiovascular risk. This study is aimed at evaluating the effect of ubiquinol supplementation, a potent lipophilic antioxidant, on oxLDL levels in prediabetic patients. Methods: This was a prospective, randomized, double-blinded, placebo-controlled pilot study of 20 adults with impaired fasting plasma glucose (FPG). Participants were randomized to receive either ubiquinol (100 mg/day) or placebo for 12 weeks. Plasma oxLDL levels were measured at baseline and Week 12. Results: After 12 weeks, the ubiquinol group demonstrated a significant within-group reduction in plasma oxLDL compared with baseline ( Conclusions: Daily ubiquinol (100 mg/day) for 12 weeks was associated with a significant within-group decrease in plasma oxLDL among prediabetic participants; however, the between-group difference versus placebo was not significant. Trial Registration: Thai Clinical Trials Registry: TCTR20250512008.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.